Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Cytek Biosciences reported mixed first quarter 2026 results. Total revenue reached $44.1 million, up 6% from a year earlier, driven by strong U.S. instrument performance and growing service and reagent revenue. GAAP gross profit was $21.3 million with a 48% gross margin, slightly below the prior year.
Operating expenses rose 13% to $39.7 million, mainly from a 43% jump in general and administrative costs tied to litigation, consulting and bad debt reserves, while research and development and sales and marketing declined modestly. Net loss widened to $18.9 million, or $0.15 per share, and adjusted EBITDA loss increased to $9.1 million.
Cytek ended March 31, 2026 with $262.2 million in cash and marketable securities, slightly above year-end. The company reaffirmed its 2026 revenue outlook of $205 million to $212 million, implying 2% to 5% growth over full-year 2025.
Cytek Biosciences, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 10, 2026 at 11:00 a.m. Pacific Time. Stockholders of record at the close of business on April 13, 2026, when 129,142,587 common shares were outstanding, may vote online.
Investors will vote on electing three Class II directors (Vera Imper, Ph.D., Glenn P. Muir and Ming Yan, Ph.D.), a non-binding advisory “say‑on‑pay” resolution on 2025 executive compensation, and ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.
The proxy describes Cytek’s classified board structure, majority of independent directors, lead independent director role, board committees, stockholder engagement after prior voting concerns, remediation of material weaknesses in internal control over financial reporting as of December 31, 2025, and strict policies against insider hedging, pledging and short sales.
Cytek Biosciences ownership filing: Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of 6,638,827 shares of Common Stock, representing 5.2% of the class as of the filing. The holders executed a joint filing agreement dated April 8, 2026.
The filing lists the issuers' principal executive office in Fremont, California, and identifies the securities by CUSIP 23285D109. The reporting persons state voting and dispositive power as shared through affiliated entities.
Cytek Biosciences Inc Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned, representing 0% of the class as reported in the amendment.
The filing notes an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or business divisions to report separately; Vanguard states it no longer is deemed to have beneficial ownership of securities held by those entities.
Cytek Biosciences, Inc. director and chief technology officer Yan Ming reported a bona fide gift of 1,176,000 shares of Common Stock. The transfer carried a reported price of $0.00 per share, reflecting that it was a non-cash gift, not a market sale. After this disposition, Ming’s direct holdings are reported at 4,915,933 Common Stock shares, indicating he retains a substantial ownership position in the company.
Cytek Biosciences director Richard Chin exercised restricted stock units into common shares. On this date, 6,107 Restricted Stock Units converted into 6,107 shares of common stock at no exercise price. After the transaction, he directly holds 16,285 shares of common stock and 57,004 Restricted Stock Units.
The footnotes explain that each RSU represents a contingent right to one share of common stock and describe a multi‑date vesting schedule, with portions of the award vesting on specified dates in August, November, March, and May until fully vested.
Cytek Biosciences, Inc. Chief Legal Officer Valerie Barnett reported equity compensation and vesting activity. She received a stock option grant for 120,114 shares of common stock at an exercise price of $4.23 per share, vesting monthly over four years. She was also granted 226,453 restricted stock units (RSUs) that vest over four years on specified May, August, November, and March dates. On the same date, several earlier RSU awards vested, converting a total of 29,722 RSUs into common shares. Of these, 11,748 shares were withheld at $4.23 per share to cover tax obligations, and the remainder increased her directly held common stock to 134,436 shares. These are compensation-related grants, exercises, and tax withholdings rather than open‑market purchases or sales.
Cytek Biosciences SVP Philippe Busque reported equity compensation and vesting activity. On March 10, 2026 he received an employee stock option for 70,665 shares of common stock at an exercise price of $4.23 per share, vesting monthly over four years. He was also granted 133,226 restricted stock units, each representing one share of common stock, scheduled to vest over four years under specified annual dates.
On the same date, several existing RSU awards vested, leading to the issuance of 9,828 shares of common stock through derivative exercises, while 3,043 shares were withheld by the company at $4.23 per share to cover tax obligations. Following these transactions, Busque directly held 35,687 shares of common stock.
Cytek Biosciences President and CEO Wenbin Jiang reported several equity compensation transactions. He was granted an employee stock option for 485,545 shares of common stock at an exercise price of $4.23 per share, vesting monthly over four years, and a new award of 915,407 restricted stock units (RSUs) that also vest over four years on specified May, August, November, and March dates.
On the same date, previously granted RSUs vested and were converted into common stock in tranches of 15,708, 29,467, and 38,669 shares. To satisfy tax withholding obligations from these vestings, 3,825, 7,747, and 9,416 shares of common stock were surrendered back to the company at $4.23 per share. After these transactions, Jiang directly owned 5,422,683 shares of common stock.